Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Recurrence 1Neoplasm Metastasis 1Carcinoma 1

Interventions

Cetuximab 14Cisplatin 12pembrolizumab 11Paclitaxel 9Gemcitabine 9durvalumab 6Nivolumab 6Docetaxel 6toripalimab 5Carboplatin 5Radiotherapy 4Fluorouracil 4Cyclophosphamide 4fludarabine 3Valproic Acid 3Capecitabine 3tremelimumab 2spartalizumab 2nimotuzumab 2irinotecan sucrosofate 2fludarabine phosphate 2cemiplimab 2anlotinib 2Sunitinib 2S 1 (combination) 2Radiation 2Oxaliplatin 2NVP-BKM120 2Methotrexate 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × pepinemab × Head & Neck × Clear all
NCT04815720 2025-01-08

KEYNOTE-B84

Vaccinex Inc.

Phase 1/2 Completed
49 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡